key papersKey paper
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia
The 2020 European LeukemiaNet recommendations set the response milestones for kinase inhibitor therapy in chronic myeloid leukaemia, when to switch drugs, and how to manage accelerated and blast phase, including transplant.
Overview
Consensus recommendations covering diagnosis, risk scoring (ELTS), first-line and later-line tyrosine kinase inhibitors, molecular response milestones, treatment-free remission, and the management of advanced-phase disease with kinase inhibitors, chemotherapy and allogeneic transplantation.
GuidelineChanged practice
Authors
Hochhaus A, Baccarani M, Silver RT, et al.
Published
Leukemia, 2020
What it means
Whether a patient is on track at three, six and twelve months, and when a change of drug or a transplant referral is warranted, is judged against these milestones.
Caveats
- Asciminib and later ponatinib dose data postdate the document.